Physician profile
Keith C Stube
NPI 1053377325
$4,023.74
in general payments reported to CMS, 2019-2025
21 companies · $535 in 2025
The $535 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $1,086 · 2021: $583 · 2022: $297 · 2023: $582 · 2024: $382 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338 · Travel and Lodging: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.09 |
| Travel and Lodging | $160.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $594.22 | 2020 | |
| Depuy Synthes Sales INC. | $516.03 | 2019-2025 | Monovisc, Orthovisc |
| Pacira Therapeutics, INC. | $504.61 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $473.14 | 2019-2025 | Euflexxa |
| Smith+Nephew, INC. | $393.90 | 2019-2025 | Healicoil, Bone Anchors With Arthroscopic Delivery System, Q-Fix |
| Arthrex, INC. | $229.95 | 2025 | |
| Medical Device Business Services, INC. | $214.99 | 2019-2023 | Attune |
| Stryker Corporation | $172.50 | 2020 | |
| Innovation Technologies INC | $157.77 | 2023 | Irrisept |
| Avanos Medical | $127.13 | 2019-2024 | Grpro 2.1 |
| Fidia Pharma USA INC. | $126.04 | 2022-2025 | Hymovis, Triluron, Hyalgan |
| Zimmer Biomet Holdings, INC. | $103.07 | 2021-2024 | Tapestry, Persona |
| Horizon Therapeutics Plc | $86.03 | 2019-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $85.52 | 2019-2023 | |
| Amgen INC. | $55.14 | 2024 | Krystexxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $40.66 | 2024 | Licart, Tirosint |
| Pacira Pharmaceuticals Incorporated | $40.60 | 2019-2022 | |
| Abbott Laboratories | $35.30 | 2025 | Proclaim, Eterna |
| Curonix LLC | $31.39 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vericel Corporation | $21.53 | 2022 | |
| Merck Sharp & Dohme LLC | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Stube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.